Fig. 3From: Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trialsAny adverse drug events associated with 100 and 300 mg canagliflozin (mean follow-up ranging from 12 to 104 weeks)Back to article page